Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

4
Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
4
Preclinical Development: Overview01:28

Preclinical Development: Overview

6.6K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
6.6K
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies01:22

Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies

1.2K
The key clinical manifestations of Rheumatic heart disease (RHD) include several distinct cardiac symptoms.Carditis, a hallmark of acute rheumatic fever, involves inflammation of the heart's endocardium, myocardium, and pericardium. Chronic RHD often results from recurrent episodes of carditis. Its symptoms include the following:Murmurs are caused by valvular damage, especially to the mitral and aortic valves. Mitral stenosis or regurgitation is common, with characteristic heart murmurs...
1.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Persistent CD4<sup>+</sup> T cell hyporesponsiveness during recovery from prolonged symptomatic SARS-CoV-2 infection.

Cellular immunology·2026
Same author

Serum proteomic atlas reveals distinct molecular signatures of lupus nephritis activity, chronicity, and treatment response.

bioRxiv : the preprint server for biology·2026
Same author

Deep profiling of lupus nephritis kidneys reveals dynamic changes in myeloid cells associated with disease progression.

Annals of the rheumatic diseases·2026
Same author

Clinical, Histologic, and Serological Predictors of Renal Function Loss in Lupus Nephritis.

Arthritis care & research·2026
Same author

Human hypofunctional NCF1 variant aggravates salivary gland immunopathology in Sjögren's disease by promoting switched memory B-cell recruitment and long-lived plasma cell differentiation.

Annals of the rheumatic diseases·2026
Same author

A population-scale atlas of blood and tissue in lupus nephritis.

bioRxiv : the preprint server for biology·2026

Related Experiment Video

Updated: Apr 20, 2026

The bm12 Inducible Model of Systemic Lupus Erythematosus SLE in C57BL/6 Mice
12:04

The bm12 Inducible Model of Systemic Lupus Erythematosus SLE in C57BL/6 Mice

Published on: November 1, 2015

19.2K

Preclinical systemic lupus erythematosus.

Julie M Robertson1, Judith A James2

  • 1Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, 825 Northeast 13th Street, Oklahoma City, OK 73104, USA.

Rheumatic Diseases Clinics of North America
|December 2, 2014
PubMed
Summary
This summary is machine-generated.

Preclinical lupus involves early signs like autoantibodies before full diagnosis. Identifying these biomarkers is key for monitoring and understanding lupus pathogenesis.

Keywords:
AutoantibodiesIncomplete lupusLupusPreclinical autoimmunitySLE

More Related Videos

Analyses of Proteinuria, Renal Infiltration of Leukocytes, and Renal Deposition of Proteins in Lupus-prone MRL/lpr Mice
09:43

Analyses of Proteinuria, Renal Infiltration of Leukocytes, and Renal Deposition of Proteins in Lupus-prone MRL/lpr Mice

Published on: June 8, 2022

3.7K
Skin Biopsy for Diagnosing Discoid Lupus Erythematosus
05:44

Skin Biopsy for Diagnosing Discoid Lupus Erythematosus

Published on: June 10, 2025

1.6K

Related Experiment Videos

Last Updated: Apr 20, 2026

The bm12 Inducible Model of Systemic Lupus Erythematosus SLE in C57BL/6 Mice
12:04

The bm12 Inducible Model of Systemic Lupus Erythematosus SLE in C57BL/6 Mice

Published on: November 1, 2015

19.2K
Analyses of Proteinuria, Renal Infiltration of Leukocytes, and Renal Deposition of Proteins in Lupus-prone MRL/lpr Mice
09:43

Analyses of Proteinuria, Renal Infiltration of Leukocytes, and Renal Deposition of Proteins in Lupus-prone MRL/lpr Mice

Published on: June 8, 2022

3.7K
Skin Biopsy for Diagnosing Discoid Lupus Erythematosus
05:44

Skin Biopsy for Diagnosing Discoid Lupus Erythematosus

Published on: June 10, 2025

1.6K

Area of Science:

  • Rheumatology
  • Immunology
  • Systemic Lupus Erythematosus (SLE) research

Background:

  • Preclinical lupus exists on a spectrum, from elevated SLE risk to individuals with autoantibodies and some symptoms not meeting full classification.
  • Biomarkers, including antibodies and serological markers, can be detected years before clinical SLE onset.
  • Conditions like incomplete lupus and undifferentiated connective tissue disease can occur during preclinical phases, with a minority progressing to SLE.

Purpose of the Study:

  • To characterize biomarkers indicative of early disease stages in lupus.
  • To identify individuals who may benefit from close monitoring or early intervention strategies.
  • To investigate the mechanisms driving lupus pathogenesis, free from confounding factors of existing treatments or organ damage.

Main Methods:

  • Review of existing literature on preclinical lupus and biomarker identification.
  • Analysis of serological and antibody data from individuals at various stages of lupus development.
  • Comparative studies of individuals with preclinical lupus, incomplete lupus, and established SLE.

Main Results:

  • Established that preclinical lupus spans a range from asymptomatic risk to symptomatic, unclassified disease.
  • Confirmed the presence of predictive antibody and serological biomarkers years prior to SLE diagnosis.
  • Noted that while incomplete lupus and UCTD can be preclinical indicators, only a fraction progress to SLE, often with mild courses.

Conclusions:

  • Further research is essential to fully characterize early disease biomarkers in lupus.
  • Identifying individuals in preclinical stages can guide monitoring and preventive interventions.
  • Understanding lupus pathogenesis requires studying the disease before immunosuppressive treatments or organ damage complicate findings.